Mechanism of Action

PARP inhibition with TALZENNA1
TALZENNA is an inhibitor of PARP enzymes, including PARP1 and PARP2, which play a role in DNA repair1
In vitro studies with cancer cell lines that harbored defects in DNA repair genes, including BRCA 1 and 2, have shown that TALZENNA-induced cytotoxicity may involve1,2:
Inhibition of PARP enzymatic activity and the
subsequent recruitment of DNA repair proteins

Increased formation of PARP-DNA complexes
  • In vitro studies showed TALZENNA-induced cytotoxicity resulted in DNA damage, decreased cell proliferation, and apoptosis1
  1. TALZENNA [prescribing information]. New York, NY: Pfizer Inc; 2018.
  2. Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13:188. doi:10.1186/s12916-015-0425-1.